Using a new method to deliver inhaled nitric oxide for patients with severe respiratory failure
Electrochemically Generated Inhaled Nitric Oxide (iNO) delivery via High Flow Nasal Cannula (HFNC)
This study is testing a new way to help people with serious breathing problems, like those caused by COVID-19, by using a special nasal device to deliver a gas called nitric oxide that can improve their oxygen levels without needing a breathing machine.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11012308 on NIH RePORTER |
What this research studies
This research investigates a novel way to deliver inhaled nitric oxide (iNO) using a high flow nasal cannula (HFNC) for patients suffering from acute hypoxemic respiratory failure, particularly those with COVID-19 or severe respiratory infections. The approach aims to improve oxygenation in these patients by providing a non-invasive method that could reduce the need for mechanical ventilation. The study utilizes an innovative electrochemical method to generate nitric oxide on-demand, making it safer and more cost-effective than traditional methods. By delivering higher and more controlled levels of nitric oxide directly to the lungs, the research seeks to enhance treatment outcomes for patients with severe lung conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are experiencing acute hypoxemic respiratory failure.
Not a fit: Patients with chronic respiratory conditions or those who do not have acute hypoxemic respiratory failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve oxygenation and overall outcomes for patients with acute respiratory failure.
How similar studies have performed: Previous research has shown promising results with inhaled nitric oxide in critical care settings, indicating that this approach could be a significant advancement in treatment.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Lautner, Gergely — University of Michigan at Ann Arbor
- Study coordinator: Lautner, Gergely
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.